Definium CFO awarded 125,000 performance shares

Definium Therapeutics’ CFO received 125,000 performance-linked shares, bringing her direct holdings to 397,905 common shares.

Rhea-AI Filing Summary

Definium Therapeutics, Inc. (DFTX) reported that its Chief Financial Officer, Brandi Roberts, received a grant of 125,000 common shares on September 14, 2026 as a performance share unit (PSU) award. These shares are part of the third tranche of PSUs granted effective June 2, 2025 and remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Roberts directly holds 397,905 common shares, which include 918 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Roberts Brandi

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1, F2	125,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 397,905 shares (Direct)

Footnotes (2)

1. F1. The common shares represent the third tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
2. F2. Amount includes 918 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.

Key Figures

Shares granted: 125,000 shares Post-transaction holdings: 397,905 shares ESPP shares acquired: 918 shares +2 more

5 metrics

Shares granted 125,000 shares Common shares granted to the CFO on September 14, 2026 as PSU award

Post-transaction holdings 397,905 shares Total common shares directly held by the CFO after the grant

ESPP shares acquired 918 shares Shares acquired under the 2024 Employee Share Purchase Plan on August 17, 2026

Vesting end date June 2, 2028 PSUs remain subject to vesting based on continued employment through this date

Grant effective date June 2, 2025 Performance share units originally granted effective on this date

Key Terms

performance share units, Employee Share Purchase Plan, clinical and regulatory milestones

3 terms

performance share units financial

"The common shares represent the third tranche of performance share units granted"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

Employee Share Purchase Plan financial

"shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan"

A program that lets employees buy their employer’s stock, often through regular payroll deductions and sometimes at a discounted price or with matching contributions; think of it as a company-run savings plan that converts part of pay into ownership. It matters to investors because it can increase insider ownership and employee motivation, potentially affecting company performance, and can slightly change share supply when new stock is issued or sold.

clinical and regulatory milestones medical

"subject to, the achievement of certain clinical and regulatory milestones"

Clinical and regulatory milestones are the key steps a medical product must clear as it is tested on patients and reviewed by government health authorities, such as completing major clinical trials, filing safety and effectiveness data, or receiving marketing approval. Investors watch these checkpoints like milestones on a roadmap because each one sharply changes the odds that a product will reach patients and generate revenue, much like a car passing inspection before it can be sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DFTX disclose for its CFO Brandi Roberts?

Definium Therapeutics disclosed that CFO Brandi Roberts received a grant of 125,000 common shares on September 14, 2026 as part of a performance share unit award that vests through June 2, 2028 based on continued employment and specified clinical and regulatory milestones.

How many DFTX shares does the CFO hold after this Form 4 transaction?

After the reported transaction, CFO Brandi Roberts directly holds 397,905 common shares of Definium Therapeutics, Inc. This total includes 918 shares acquired under the company’s 2024 Employee Share Purchase Plan on August 17, 2026.

What are the key vesting conditions for the 125,000 DFTX performance share units?

The 125,000 performance share units represent the third tranche of PSUs granted effective June 2, 2025. They remain subject to vesting based on continued employment through June 2, 2028 and the achievement of specified clinical and regulatory milestones under the award agreement.

Was the DFTX CFO’s September 14, 2026 share grant made under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan for this transaction; the document-level Rule 10b5-1 checkbox is marked as not affirmed, and the footnotes do not state that the award was made under such a plan.

How many DFTX shares were acquired under the 2024 Employee Share Purchase Plan by the CFO?

CFO Brandi Roberts acquired 918 common shares of Definium Therapeutics, Inc. under the 2024 Employee Share Purchase Plan on August 17, 2026. These ESPP shares are included in her total of 397,905 directly held common shares after the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 08:30 AM Accepted by SEC EDGAR 09/14/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Brandi

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/14/2026		A		125,000(1)	A	$0.00	397,905(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The common shares represent the third tranche of performance share units granted effective June 2, 2025, and remain subject to vesting based on the Reporting Person's continued employment through June 2, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

2. Amount includes 918 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.

	/s/ Mark Sullivan, Attorney-in-Fact for Brandi Roberts	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)